Though severe pediatric asthma only represents from 2 to 5% of the children suffering with this condition, it represents a major share of the cost, resource utilization, and morbidity. It is important that allergists have a good gasp of this condition and how it differs from the adult population. Topics include appropriate workup, comorbidities, steroid burden.

To download the mp3 file, right click on the player and select Save audio as.

Host: Gerald Lee, MD, FACAAI
Expert: Wanda Phipatanakul, MD, MS, FACAAI
Expert: Pricess Ogbogu, MD, FACAAI
Expert: William Anderson III, MD, FACAAI

Learning Objectives:

  1. Be able to discuss the burden of severe pediatric asthma and issues in optimal medication adherence in this population
  2. Be able to evaluate the child with severe asthma and screen for corticosteroid overuse in and remedies to decrease it in this population
  3. Be able to interpret the mechanisms of action, applicable pediatric population, dosing, outcome data, and adverse effects of current and future treatments beyond standard therapy in severe pediatric asthma


  1. Perry, R., Braileanu, G., Palmer, T. et al. The Economic Burden of Pediatric Asthma in the United States: Literature Review of Current Evidence. PharmacoEconomics 37, 155–167 (2019).
  2. Yao T, Wang J, Chang S, et al. Association of Oral Corticosteroid Bursts With Severe Adverse Events in Children. JAMA Pediatr. Published online April 19, 2021.
  3. Katial RK, Bensch GW, Busse WW, Chipps BE, Denson JL, Gerber AN, et al. Changing paradigms in the treatment of severe asthma: the role of biologic therapies. J Allergy Clin Immunol Pract 2017;5:S1–S14.
  4. Licari, A., Manti, S., Castagnoli, R. et al. Targeted Therapy for Severe Asthma in Children and Adolescents: Current and Future Perspectives. Pediatr Drugs 21, 215–237 (2019)

This podcast series is supported by Sanofi Regeneron.